What is SYNAPS Dx?
Based in Rockville, MD, SYNAPS Dx is a medical research and development firm dedicated to advancing the understanding and treatment of neurodegenerative disorders. The company's focus on this critical area of medical science positions it within a rapidly evolving and highly competitive biotechnology landscape. Its strategic objective is to develop innovative solutions for conditions impacting millions globally.
How much funding has SYNAPS Dx raised?
SYNAPS Dx has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2021): $10M, investors not publicly disclosed
What's next for SYNAPS Dx?
The recent enterprise-level funding suggests SYNAPS Dx is poised for significant scaling and further research and development initiatives. This capital injection will likely accelerate its pipeline, potentially enabling clinical trials, expanding its research team, and forging strategic partnerships within the healthcare and pharmaceutical sectors. The company's continued focus on neurodegenerative diseases indicates a long-term commitment to addressing unmet medical needs.
See full SYNAPS Dx company page
